Drug intelligence / Profile preview

HTK03121

Development stage
Preclinical
Lead developer
BC Cancer
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
Administration
Intravenous
01

Overview

HTK03121 is a prostate-specific membrane antigen (PSMA)-targeting radiopharmaceutical developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is a DOTA-conjugated lysine-ureido-glutamate-based ligand that incorporates a tranexamic acid-9-anthrylalanine affinity-modifying group and an N-(4-(p-chlorophenyl)butanoyl)-Gly albumin-binding motif. The albumin binder is designed to enhance the blood residence time, thereby increasing tumor accumulation and improving the tumor-to-kidney absorbed dose ratio. Preclinical evaluations using Lutetium-177 (177Lu) labeling have shown that HTK03121 achieves significantly higher tumor uptake compared to the standard-of-care PSMA-617, suggesting potential for improved therapeutic efficacy with lower administered doses.

Other names
177Lu-HTK03121
02

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on HTK03121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HTK03121.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call